These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9691222)

  • 21. Definition of the region on NS3 which contains multiple epitopes recognized by dengue virus serotype-cross-reactive and flavivirus-cross-reactive, HLA-DPw2-restricted CD4+ T cell clones.
    Okamoto Y; Kurane I; Leporati AM; Ennis FA
    J Gen Virol; 1998 Apr; 79 ( Pt 4)():697-704. PubMed ID: 9568963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein.
    Martin P; Parroche P; Pajot A; Chatel L; Barreto C; Touat L; Dubois V; Rohrlich PS; Bain C; Trépo C; Negro F; Inchauspé G; Fournillier A
    Microbes Infect; 2006 Aug; 8(9-10):2432-41. PubMed ID: 16859951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal mapping of protective CD4+ T cell responses against HCV: analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes.
    Harcourt GC; Lucas M; Sheridan I; Barnes E; Phillips R; Klenerman P
    J Viral Hepat; 2004 Jul; 11(4):324-31. PubMed ID: 15230855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy.
    Li W; Krishnadas DK; Li J; Tyrrell DL; Agrawal B
    J Immunol; 2006 May; 176(10):6065-75. PubMed ID: 16670315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated dermal fibroblasts.
    Maurer DH; Hanke JH; Mickelson E; Rich RR; Pollack MS
    J Immunol; 1987 Aug; 139(3):715-23. PubMed ID: 3110281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ELISPOT analysis of hepatitis C virus protein-specific IFN-gamma-producing peripheral blood lymphocytes in infected humans with and without cirrhosis.
    Anthony DD; Post AB; Valdez H; Peterson DL; Murphy M; Heeger PS
    Clin Immunol; 2001 May; 99(2):232-40. PubMed ID: 11318595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Th1 and Th2 cytokine profiles induced by hepatitis C virus F protein in peripheral blood mononuclear cells from chronic hepatitis C patients.
    Yue M; Deng X; Zhai X; Xu K; Kong J; Zhang J; Zhou Z; Yu X; Xu X; Liu Y; Zhu D; Zhang Y
    Immunol Lett; 2013 May; 152(2):89-95. PubMed ID: 23680070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
    Quiroga JA; Llorente S; Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Pardo M; Carreño V
    J Med Virol; 2006 Sep; 78(9):1190-7. PubMed ID: 16847959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial).
    Chernykh E; Leplina O; Oleynik E; Tikhonova M; Tyrinova T; Starostina N; Ostanin A
    Immunol Res; 2018 Feb; 66(1):31-43. PubMed ID: 29164490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human anti-idiotypic T lymphocyte clones are activated by autologous anti-rabies virus antibodies presented in association with HLA-DQ molecules.
    UytdeHaag F; Claassen I; Bunschoten H; Loggen H; Ottenhoff T; Teeuwsen V; Osterhaus A
    J Mol Cell Immunol; 1987; 3(3):145-55. PubMed ID: 2908179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection.
    Wong DK; Dudley DD; Afdhal NH; Dienstag J; Rice CM; Wang L; Houghton M; Walker BD; Koziel MJ
    J Immunol; 1998 Feb; 160(3):1479-88. PubMed ID: 9570570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients.
    Godkin A; Jeanguet N; Thursz M; Openshaw P; Thomas H
    Eur J Immunol; 2001 May; 31(5):1438-46. PubMed ID: 11465100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073.
    Fytili P; Dalekos GN; Schlaphoff V; Suneetha PV; Sarrazin C; Zauner W; Zachou K; Berg T; Manns MP; Klade CS; Cornberg M; Wedemeyer H
    Vaccine; 2008 Jul; 26(31):3818-26. PubMed ID: 18582999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A hepatitis C virus (HCV) core protein derived peptide inhibits HCV specific lymphocyte proliferation.
    Langhans B; Lechmann M; Ihlenfeldt H; Jung G; Giers G; Schweitzer S; El Bakri M; Sauerbruch T; Spengler U
    Eur J Med Res; 2000 Mar; 5(3):115-20. PubMed ID: 10756165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide-induced T cell clones: specificity, MHC restriction, proliferation and cytokine pattern as a function of different stimulations.
    Pichler WJ; Brander C; Mauri D; Frutig K; Wyss-Coray T
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1994; (87):141-53; discussion 153-4. PubMed ID: 7873053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response.
    Rollier C; Depla E; Drexhage JA; Verschoor EJ; Verstrepen BE; Fatmi A; Brinster C; Fournillier A; Whelan JA; Whelan M; Jacobs D; Maertens G; Inchauspé G; Heeney JL
    J Virol; 2004 Jan; 78(1):187-96. PubMed ID: 14671100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.
    Walker A; Skibbe K; Steinmann E; Pfaender S; Kuntzen T; Megger DA; Groten S; Sitek B; Lauer GM; Kim AY; Pietschmann T; Allen TM; Timm J
    J Virol; 2016 Jan; 90(1):33-42. PubMed ID: 26446603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals.
    Vertuani S; Bazzaro M; Gualandi G; Micheletti F; Marastoni M; Fortini C; Canella A; Marino M; Tomatis R; Traniello S; Gavioli R
    Eur J Immunol; 2002 Jan; 32(1):144-54. PubMed ID: 11754355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular immune responses and occult infection in seronegative heterosexual partners of chronic hepatitis C patients.
    Roque-Cuéllar MC; Sánchez B; García-Lozano JR; Praena-Fernández JM; Núñez-Roldán A; Aguilar-Reina J
    J Viral Hepat; 2011 Oct; 18(10):e541-9. PubMed ID: 21914075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.